Health Canada Removes Finished Product Specifications (FPS) Submission Requirement for NHP Applications: What Manufacturers Need to Know

Health Canada has announced an important regulatory update affecting Natural Health Product (NHP) licence holders and applicants across Canada. Effective June 25, 2026, Finished Product Specifications (FPS) are no longer expected to be submitted as part of Class II and Class III Product Licence Applications (PLAs) or amendment submissions.

This represents one of the most significant administrative changes to Canada’s NHP licensing framework in recent years. While the update reduces documentation submitted during licensing, it does not reduce a company’s responsibility to maintain compliant quality systems and Good Manufacturing Practices (GMP).

For manufacturers, importers, private-label brand owners, and regulatory affairs professionals, understanding this change is essential to remain compliant while benefiting from a more streamlined licensing process.

What Are Finished Product Specifications (FPS)?

Finished Product Specifications (FPS) are documented quality standards established before a Natural Health Product is released for sale.

These specifications verify that products consistently meet predefined requirements for:

• Identity
• Potency
• Purity
• Quality
• Safety
• Shelf-life consistency

An FPS typically contains analytical specifications, microbiological limits, physical and chemical characteristics, testing methods, acceptance criteria, and stability requirements.

Although submission requirements have changed, FPS documents remain an essential component of every manufacturer’s Quality Management System.

What Has Changed?

Effective June 25, 2026:

• Finished Product Specifications are no longer routinely expected as part of Class II and Class III Product Licence Applications.
• Changes affecting only FPS documents generally no longer require amendment submissions.

The objective is to reduce administrative burden while allowing Health Canada to focus regulatory resources on higher-risk compliance activities.

However, Health Canada may still request FPS documentation during:

• Application reviews
• GMP inspections
• Information requests
• Compliance verification activities
• Post-market surveillance

What Has Not Changed?

The most important message for industry is that quality obligations remain exactly the same.

Companies must continue to:

• Maintain current Finished Product Specifications
• Operate compliant GMP systems
• Maintain document control
• Perform product testing
• Ensure specifications remain inspection-ready

The policy changes submission expectations—not quality expectations.

Why Health Canada Introduced This Update

Health Canada continues moving toward a modern, risk-based regulatory model.
Instead of reviewing every supporting document during licensing, regulators increasingly focus on:

• GMP compliance
• Quality systems
• Inspection outcomes
• Risk management
• Post-market oversight

This approach aligns Canada with international regulatory trends emphasizing manufacturer accountability and quality management.

Impact on Manufacturers and Importers

The revised policy reduces paperwork and may shorten licence preparation activities.
However, organizations should use this opportunity to strengthen internal compliance systems by reviewing:

• Document control procedures
• Supplier qualification programs
• Change control systems
• Product testing programs
• Quality Management Systems

Reduced submissions do not mean reduced inspections.

Why GMP Compliance Remains Critical

Finished Product Specifications remain a core GMP requirement because they define the standards against which every batch is evaluated.
During inspections, Health Canada may assess whether specifications are:

• Scientifically justified
• Current
• Properly approved
• Consistently implemented
• Supported by appropriate testing

Strong documentation remains essential for inspection readiness.

Common Compliance Risks

Organizations should avoid common mistakes including:

• Maintaining outdated FPS documents
• Weak document control systems
• Unsupported specification limits
• Poor change management
• Assuming FPS documents are no longer important

Inspection readiness remains essential because Health Canada may request these records at any time.

What Foreign Manufacturers Should Know
International manufacturers exporting Natural Health Products to Canada should recognize that this policy simplifies licensing—but does not reduce Canadian regulatory expectations.

Companies must still comply with:

• NHP licensing requirements
• Canadian GMP requirements
• Label compliance
• Product quality documentation
• Inspection readiness

Working with experienced regulatory consultants can help reduce approval delays and compliance risks.

Practical Steps Companies Should Take

Organizations should consider:

• Reviewing all Finished Product Specifications
• Verifying scientific justification for specification limits
• Strengthening document approval workflows
• Training regulatory and quality personnel
• Conducting internal GMP reviews
• Maintaining organized inspection-ready documentation

These proactive measures help organizations benefit from streamlined submissions while maintaining regulatory compliance.

Frequently Asked Questions

Does Health Canada still require Finished Product Specifications?
Yes. Companies must maintain compliant FPS documents and provide them when requested.

Do FPS-only revisions require amendment submissions?
Generally, no. FPS-only changes are no longer routinely expected to be submitted as amendments.

Does this change affect GMP requirements?
No. All GMP obligations remain fully applicable.

Can Health Canada still review FPS documents?
Yes. FPS documents may be requested during inspections, compliance activities, or application reviews.

How Fiducia Globus Supports NHP Companies

Fiducia Globus supports Natural Health Product manufacturers through:

• Product Licence Applications
• Finished Product Specification development and review
• GMP compliance consulting
• SOP development
• Regulatory gap assessments
• Inspection readiness programs
• Canadian market entry consulting
• Ongoing regulatory support

Our practical regulatory approach helps manufacturers maintain compliance while navigating evolving Health Canada requirements.

Conclusion

Health Canada’s decision to remove routine FPS submissions for Class II and III Product Licence Applications reduces administrative burden but does not reduce regulatory accountability.

Organizations with strong GMP systems, robust documentation, and effective quality management practices will be best positioned to benefit from this streamlined licensing approach while remaining fully compliant with Health Canada expectations.